(JNJ) stock has risen 55.3% over the past year, even as it slipped 0.2% in the last week and 5.8% over the past month. Wall Street’s analysts are moderately bullish, forecasting further gains over the next twelve months with an average price target of $264.73 versus the last close of $224.26.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Johnson & Johnson’s current analyst consensus stands at Moderate Buy, suggesting a cautious but positive stance among experts. The 12‑month price target implies meaningful upside from current levels, signaling that many on Wall Street still see room for the rally to continue.
David Risinger (Leerink Partners) upgraded JNJ to Buy on 5/13/2026 and raised his price target to $265.00, implying upside from the latest share price. He lifted the target from $252 after boosting his long‑term revenue and earnings growth assumptions.
Risinger’s report highlights strong momentum from new drugs as the core of his bullish thesis. He expects accelerating revenue growth powered by Icotyde, Inlexzo, Rybrevant and Tremfya, and believes this could drive stock outperformance over time.
This 5‑star analyst ranks 87 out of 12,188 on TipRanks, with a 63.21% success rate and an impressive 30.30% average return per rating. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.